The role of antinuclear autoantibodies in patients with psoriasis treated with anti–tumor necrosis factor-alpha agents: A retrospective long-term study - 16/04/12
Doi : 10.1016/j.jaad.2011.06.008
Rosita Saraceno, MD a, ⁎, Francesca Specchio, MD a, Tiago Torres, MD c, Steven Paul Nisticò, MD a, Stefano Rizza, MD b, Sergio Chimenti, MD a
a Department of Dermatology, University of Rome Tor Vergata, Italy
b Department of Internal Medicine, University of Rome Tor Vergata, Italy
c Department of Dermatology, Hospital Santo António, Porto, Portugal
Correspondence to: Rosita Saraceno, MD, Department of Dermatology, Policlinico tor Vergata, Viale Oxford 81 00133, Rome| Funding sources: None. |
|
| Conflicts of interest: Dr Chimenti has received speaker fees, consultancy fees and research grants from Schering-Plough/Merck, the manufacturers of infliximab. Dr Saraceno has received a speaker fee from Schering-Plough/Merck. |
© 2011
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 66 - N° 5
P. e180-e182 - mai 2012 Retour au numéro
Article précédent
- Effects of contiguous scars in dermatoscopic evaluation of clinically atypical melanocytic nevi
- Hyuk C. Cha, Mandy Harting, Kelly B. Cha, Mathew W. Ludgate, Stephen H. Olsen, Lili Zhao, Christopher D. Lao
- A high serum concentration of chemerin in pustular dermatitis paradoxically induced by etanercept
- Yu Sawada, Motonobu Nakamura, Kayo Hama, Ryosuke Hino, Yoshiki Tokura
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?